“…In another trial, 50 patients received a single intravenous dose of liposomal curcumin in the range of 10–400 mg/m 2 over 2 h. While the dosages ≥120 mg/m 2 already changed the red blood cell morphology, the curcumin and its metabolites in plasma became undetectable within 6–60 min [ 19 ]. In order to improve the bioavailability of curcumin, a variety of nanocarriers for curcumin have been developed [ 20 , 21 , 22 ], including polymer micelles [ 23 , 24 , 25 , 26 ], liposomes [ 27 , 28 , 29 , 30 ], inorganic nanoparticles [ 31 , 32 , 33 ], porous silica/metal–organic frames [ 34 , 35 , 36 ], biopolymer complexes/nanoparticles [ 37 , 38 , 39 , 40 , 41 ], and nanogels [ 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 ]. However, most of these nanocarriers developed so far exhibit a low loading capacity, which still limits the bioavailability of curcumin for clinical use.…”